Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Leqvio®
( inclisiran )Innovative Medicines -
Lescol®
( fluvastatin sodium )Cardiovascular, Renal and Metabolism -
Lescol® XL
( fluvastatin sodium )Cardiovascular, Renal and Metabolism -
Locametz®
( gallium Ga 68 gozetotide ) -
Lucentis®
( ranibizumab )Ophthalmology -
Lutathera®
( lutetium Lu 177 dotatate )Neuroendocrine TumorsAvailable in -
Luxturna®
( voretigene neparvovec )OphthalmologyAvailable in -
Mayzent®
( siponimod )Neuroscience